We aim to provide eyecare providers with transformative, clinically-proven technologies that are intuitive, less invasive, and more intelligent.
A Revolution in Eye Disease Treatment
About Us
Who we are
A Bold Vision for The Future of Eyecare
We have embarked on a journey to reimagine the landscape of eyecare. Our mission is clear: to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care — empowering people to keep seeing.
By making treatments less invasive, intuitive, and more intelligent, we envision a future where innovations are not only groundbreaking but are also employed at the earliest stages of disease progression, ensuring safe and unprecedented progress in the field of vision health.
data
by the Numbers
214
Sight Sciences employees worldwide
300,000+
Procedures performed worldwide using Sight Sciences technologies
11
Countries with access to the OMNI Surgical System
WHY SIGHT
why sight
Proven Glaucoma and OSD Treatments
Transformational Technologies
With an infinite mindset and holistic understanding of chronic eye diseases, we are delivering technologies that are less invasive, target the underlying disease and enable eyecare providers to intervene earlier in disease progression.
Trusted Partner
Consistent delivery and commercial excellence coupled with comprehensive clinical support and training gives our care providers the confidence to grow with us.
Top-Tier Clinical Evidence
Our commitment to head-to-head clinical trials and real-world results aim to demonstrate superiority vs. existing treatment gold standards.
Our Community
OUR COMMUNITY
United on a Mission to Preserve Sight
Our drive to innovate combined with proven clinical excellence has made us a trusted partner to the eyecare community.
Testimonials
“The results of the ROMEO 24-Month study give eye surgeons even greater confidence about the safety, efficacy, and durability of the OMNI procedure.”
Blake Williamson, MD
“I use OMNI in my practice very frequently. It has worked very well for my mild to moderate glaucoma patients, those with cataract surgery and those without cataract surgery.”
Christine Funke, MD
“Pharmaceutical intervention with Restasis has been the hallmark of dry eye treatment since its introduction. The results of the SAHARA RCT utilizing TearCare technology, which treats the root cause of dry eye disease, should make us rethink our options for the optimal treatment for dry eye.”
Marc R. Bloomenstein, OD, FAAO
“I have used OMNI since 2018, and I have to say with 100% confidence that it is my favorite MIGS device”
Monisha Vora, MD
“I was surprised and impressed at how smooth SION made the goniotomy procedure.”
Arkadiy Yadgarov, MD
behaviors
Picture Yourself at Sight Sciences
Love what you do.
Every day you are improving lives; it’s why we’re all here.
Have each other’s back.
Collaborate early and often and trust that people act with good intention.
Own it.
Act with integrity. Everybody is responsible for our results.
Break through walls.
Be courageous and execute with conviction, utilizing all available resources
to get the job done.
Grow, every day.
Continually find new ways to evolve and push past the status quo.
Who we are
Leadership
Paul Badawi
Founder & Chief Executive Officer
Dr. David Badawi, MD
Founder & Chief Technology Officer
Ali Bauerlein
Chief Financial Officer
Dr. Reay H. Brown, MD
Chief Medical Officer
Matt Link
Chief Commercial Officer
Jeremy Hayden
Chief Legal Officer
Brenton Taylor
EVP, Operations
MK Raheja
EVP, Research & Development
Board of Directors
Dr. David Badawi
Founder & Chief Technology Officer
Staffan Encrantz
Staffan Encrantz has served as Chairperson of the Board since 2017.
Don Zurbay
Donald Zurbay has served as a member
of our Board since July 2020.
Paul Badawi
Founder & Chief Executive Officer
Erica Rogers
Erica Rogers has served as a member
of our Board since November 2019.
Dr. Tamara Fountain, MD
Tamara Fountain has served as a member of our Board since July 2022.
Brenda Becker
Brenda Becker has served as a member
of our Board since March 2022.
Catherine Mazzacco
Catherine Mazzacco has served as a member of our Board since June 2023.
